VNRX
AMEXVolitionRX Limited
News · 26 weeks55+80%
2026-03-012026-08-23
Mix2290d
- SEC Filings12(55%)
- Other7(32%)
- Earnings2(9%)
- Offering1(5%)
Latest news
25 items- SECVolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - VOLITIONRX LTD (0000093314) (Filer)
- SECSEC Form S-8 filed by VolitionRX LimitedS-8 - VOLITIONRX LTD (0000093314) (Filer)
- SECSEC Form 10-Q filed by VolitionRX Limited10-Q - VOLITIONRX LTD (0000093314) (Filer)
- SECVolitionRX Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - VOLITIONRX LTD (0000093314) (Filer)
- PRVolitionRx Limited Announces Second Quarter 2026 Financial Results and Business UpdateConference call to discuss financial and operational results scheduled forFriday, August 14 at 8:30 a.m. U.S. Eastern TimeHENDERSON, Nev., Aug. 13, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the second quarter of 2026. Volition management will host a conference call tomorrow, August 14 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said:"We have made strong progress across all of our product pillars throughout 2026 to date."W
- PRVolition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis PatientsRemoves Centralized Lab Dependency for $3.8 Billion Global Addressable Market forNETosis TestingHENDERSON, Nev., Aug. 12, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces that results utilizing its lateral flow prototype are highly correlated with results utilizing Volition's established automated Nu.Q® NETs test in critically ill sepsis patients1 , thereby expanding beyond centralized laboratory testing. This new lateral flow finger prick sample test could be used to rapidly identify high-risk patients in the ER or at the bedside, thereby greatly expanding the potential market beyond centralized lab testing. It also has
- PRVolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business UpdateConference call to take place on Friday, August 14 at 8:30 a.m. U.S Eastern TimeHENDERSON, Nev., Aug. 11, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, August 14 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the second quarter 2026 and to provide a business update. Details of this event can be found below. Event: VolitionRx Limited Second Quarter 2026 Earnings and Business Update Conference Call Date: Friday, August 14, 2026Time: 8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European TimeU.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll free)
- SECVolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - VOLITIONRX LTD (0000093314) (Filer)
- PRVolition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy TechnologyTargets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization.HENDERSON, Nev., Aug. 5, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, was the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived DNA (ctDNA). Volition today announces the publication of the first peer-reviewed paper describing the technology in detail - entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy1". Most current liquid bi
- PRVolition Advances Nu.Q® NETs Platform Towards CommercializationConsistent international data positions Nu.Q® H3.1 as a potential "game changer" in sepsis management within a $3.8 billion addressable marketHENDERSON, Nev., July 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive update highlighting the significant clinical and scientific evidence amassed for its Nu.Q® NETs product. It also issued a video featuring Critical Care Lead and Medical Consultant to Volition, Dr Andrew Retter, who explains the scientific and clinical significance of these findings. Mr. Gael Forterre, Chief Commercial Officer, Volition commented:"We are in active di
- SECVolitionRX Limited filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - VOLITIONRX LTD (0000093314) (Filer)
- SECSEC Form EFFECT filed by VolitionRX LimitedEFFECT - VOLITIONRX LTD (0000093314) (Filer)
- SECSEC Form S-3 filed by VolitionRX LimitedS-3 - VOLITIONRX LTD (0000093314) (Filer)
- PRVolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer TestHENDERSON, Nev., July 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of a new clinical study demonstrating the significant prognostic value of its Nu.Q® Cancer Assay in newly diagnosed lung cancer patients, which could help clinicians identify patients' likely outcomes and personalize treatment selection accordingly. The clinical paper entitled "Prognostic value of circulating H3K27Me3-nucleosomes in newly diagnosed lung cancer patients: Real-world evidence1" has been written in conjunction with researchers and clinicians at the Hospices Civils de Lyon (HCL), France's second largest university hospital sy
- SECVolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - VOLITIONRX LTD (0000093314) (Filer)
- PRVolitionRx Announces Collaboration with SysmexHENDERSON, Nev., June 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces a collaboration with Sysmex (TYO:6869), a leader in global in vitro diagnostics, to optimize Volition's Nu.Q® NETs H3.1 assay on the Sysmex platform. Gael Forterre, Chief Commercial Officer, Volition commented:"We are proud to have entered into this agreement with Sysmex, as we implement our strategy to out license our proprietary Nu.Q® NETs test to large companies with a worldwide presence, to leverage their knowledge of specific diseases, product development, regulatory experience and their installed base of proprietary analyzers. Sysmex is a global le
- SECSEC Form 424B5 filed by VolitionRX Limited424B5 - VOLITIONRX LTD (0000093314) (Filer)
- PRVolitionRx Announces Pricing of $4.6 Million Public Offering$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrantsHENDERSON, Nev., June 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announced the pricing of its previously announced public offering of 2,960,000 shares of common stock, and warrants to purchase up to an aggregate of 1,480,000 shares of common stock, at a combined public offering price of $1.55 per share and accompanying half warrant. Each warrant will have an exercise price of $1.55 per share, will be exercisable immediately upon issuance, and will expire five years after the date of issuance. T
- SECSEC Form 424B5 filed by VolitionRX Limited424B5 - VOLITIONRX LTD (0000093314) (Filer)
- PRVolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment MonitoringSeeks Strategic Partners to Deploy Nu.Q® Platform in Outbreak ZonesHENDERSON, Nev., June 3, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has expanded its robust intellectual property portfolio by filing a strategic patent application covering the use of its proprietary Nu.Q® technology in triaging and monitoring patients who are suspected of having contracted the Ebola virus. Dr. Jake Micallef, Chief Scientific Officer, Volition commented:"This filing yet again shows the breadth of utility of our technology: it claims the potential use of Volition's existing Nu.Q® NETs test for Ebola. The Nu.Q® NETs test qua
- SECSEC Form DEF 14A filed by VolitionRX LimitedDEF 14A - VOLITIONRX LTD (0000093314) (Filer)
- PRVolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable MarketsUpdate Highlights 300% Q1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, and Active Licensing Discussions with More Than a Dozen Global Diagnostic LeadersHENDERSON, Nev., May 27, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today provided a comprehensive corporate update highlighting the significant clinical and commercial progress achieved over recent months. Key Highlights:First Quarter Revenue Growth: Reported $1M of revenue in the first quarter of 2026, representing a 300% increase year-over-year.Feline Lymphoma Manuscript Submission: Formally submitted the clinical manuscript for the
- SECVolitionRX Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - VOLITIONRX LTD (0000093314) (Filer)
- SECVolitionRX Limited filed SEC Form 8-K: Leadership Update8-K - VOLITIONRX LTD (0000093314) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by VolitionRX LimitedSCHEDULE 13G/A - VOLITIONRX LTD (0000093314) (Subject)
VNRX FAQ
7 questionsWhat does VolitionRX Limited do?
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q Vet Cancer Screening Test for veterinary applications. The company also develops blood-based Nu.Q immunoassays to detect specific biomarkers. In addition, it is developing various veterinary products, including a treatment monitoring test, a disease recurrence test, and a point-of-care platform. VolitionRx Limited is based in Austin, Texas.Where does VNRX stock trade?
VolitionRX Limited (VNRX) is listed on AMEX.What sector and industry is VNRX in?
VolitionRX Limited operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.When did VolitionRX Limited go public?
VolitionRX Limited (VNRX) completed its IPO in 2015.What are analysts saying about VNRX?
VolitionRX Limited has had 4 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $250.00 price target on 2025-04-08. Recent price targets range from $250.00 to $900.00.What companies are similar to VNRX?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), ORKA (Oruka Therapeutics Inc.), LNTH (Lantheus Holdings Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), CLDX (Celldex Therapeutics Inc.). Compare VNRX side-by-side with any of them on Quantisnow.How can I track VNRX on Quantisnow?
Quantisnow aggregates VolitionRX Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VNRX to receive live email and push alerts on every new disclosure.